Top news of the week: 26.05.2020.
#COVID19 #Coronavirus #biotechnology #biospace #lifesciences #pharmaceuticals #Biopharma #CoronaOutbreak #CoronaPandemic
Companies And Industries
GCPP (Biotech Policy) - The Takshashila Institution - @ABLE_INDIA @DBTIndia https://t.co/U5Hk8hytdc
Open
Biopharma Update on the Novel Coronavirus: May 22
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.
Biopharma Update on the Novel Coronavirus: May 20
#biospace #lifesciences #biotechnology #pharmaceuticals
https://t.co/0VXEHtamzD
OpenBiopharma Update on the Novel Coronavirus: May 20
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
Sinovac's #Covid19 vaccine is in human trials, but investors aren't benefiting, @damiangarde writes. Because the stock has been halted since early 2019, making it Nasdaq's longest ongoing suspension.
$SVA, not that it matters.
https://t.co/k6ZsXzMKn6
OpenA secret coup and a ‘poison pill’ have frozen shares of a biotech in the race for a Covid-19 vaccine
Sinovac is working on one of the more closely watched candidate vaccines for the disease, but trading of its shares has been long suspended.
RT @RebeccaDRobbins: The latest ep of @statnews' podcast is live. It's all about our insane new reality where everyone is a biotech day trader. We talk:
🔹 $MRNA's #covid19 vaccine press release
🔹 why biotech news is moving global markets
🔹 a brief history of $MRNA
Listen 👇
https://t.co/qmbeDtlPP1
OpenListen: Moderna’s scant coronavirus data, the plight of the day trader, and the world’s dependence on biotech
In this episode, we break down Moderna's early-stage results from a coronavirus vaccine and the reaction from unsatisfied experts around the globe.
Rentschler Biopharma Licenses @HZDiscovery CHOSOURCE Platform: https://t.co/McDQ9CSWws https://t.co/fWX9tYyN15
OpenRentschler Biopharma Licenses Horizon Discovery’s CHOSOURCE Platform
The Rentschler Biopharma and Horizon Discovery agreement is designed to enhance Rentschler’s in-house process for difficult-to-express proteins.
How Upbeat Vaccine News Fueled a Stock Surge, and an Uproar https://t.co/LDsZnQnSJB https://t.co/YK8shhNwLL
OpenHow Upbeat Vaccine News Fueled a Stock Surge, and an Uproar
The desperate hunt for treatments and vaccines has changed how researchers, regulators, drug companies like Moderna, investors and journalists do their jobs.
Kintor’s $240M IPO well received in Hong Kong; CEO says internal early stage R&D will be future focus https://t.co/MpDAECq4By
OpenKintor’s $240M IPO well received in Hong Kong; CEO says internal early stage R&D will be future focus
BEIJING – Androgen receptor (AR)-related disease specialist Kintor Pharmaceutical Ltd., of Suzhou, China, raised $240 million on the Hong Kong Stock Exchange (HKEX) on May 22 by issuing ...